Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$224.56M+501.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Dube
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 497
- Beta
- 1.12
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 1.65
Financials
Revenue
$224.56M+501.6%Net Income
$-52.34MEBITDA
$-59.59MFree Cash Flow
$98.20MEPS (diluted)
$-0.55Shares Outstanding (diluted)
94.63M+141.7%Operating Expenses
$168.72MCash & Debt
$471.82MRevenue by Segment (annual)
$490.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $490.73M | $-25.55M | $-0.56 |
| 2024 | $233.18M | $-321.55M | $-4.08 |
| 2023 | $145.24M | $-111.40M | $-1.50 |
| 2022 | $109.46M | $-278.48M | $-4.37 |
| 2021 | $131.84M | $-180.09M | $-3.01 |
| 2020 | $198.32M | $-169.43M | $-3.56 |
| 2019 | $175.34M | $-146.43M | $-3.46 |
| 2018 | $164.25M | $-102.68M | $-2.54 |
| 2017 | $154.94M | $-59.73M | $-1.54 |
| 2016 | $133.59M | $-47.90M | $-1.29 |
| 2015 | $99.89M | $117.24M | $3.49 |
| 2014 | $28.20M | $-110.94M | $-4.43 |
| 2013 | $0.00 | $-33.82M | $-2.38 |
| 2012 | $0.00 | $-30.34M | $-284.40 |
Valuation
TVTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
123+146.67%Social Signal Score
Mentions (19)
- News (RSS)seekingalpha·6d ago·Neutral
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
View source ↗ - Newsseekingalpha.com·6d ago·Neutral
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy Travere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. TVTX shares have nearly tripled since the initial 'Buy' rating in August 2025, reflecting strong momentum. With two FDA-approved revenue streams, TVTX now faces questions about sustaining its exceptional upward trajectory.
View source ↗ - Newsbusinesswire.com·19d ago·Neutral
Travere Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Biopharma ConferencePresenting on Monday, Novemb…
View source ↗ - News (RSS)seekingalpha·19d ago·Positive
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)fool·19d ago·Positive
Travere (TVTX) Q3 2026 Earnings Call Transcript FILSPARI sales hit $200.2 million as FSGS launches alongside sustained IgAN demand.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·20d ago·Neutral
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.
View source ↗ - Newsbusinesswire.com·20d ago·Positive
Travere Therapeutics Reports Third Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of…
View source ↗ - News (RSS)seekingalpha·21d ago·Neutral
Travere Therapeutics Q3 2026 Earnings Preview
View source ↗ - Newsbusinesswire.com·27d ago·Neutral
Travere Therapeutics to Report Third Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.The webcast and dial-in information can be accessed on the Investor p…
View source ↗ - Newsbusinesswire.com·30d ago·Neutral
… Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology…
View source ↗ - News (Marketaux)gurufocus.com·60d ago·Positive
TVTX Looks 57.0% Overvalued on GF Value™ On September 23, 2026, Travere [+293 characters]
View source ↗ - Newsbusinesswire.com·62d ago·Neutral
Travere Therapeutics Announces Planned Chief Executive Officer Transition SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Ph…
View source ↗ - Newsbusinesswire.com·66d ago·Neutral
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replay will be available for up to …
View source ↗ - News (RSS)investing·93d ago·Neutral
Travere Therapeutics stock hits 52-week high at 66.35 USD
View source ↗ - Newsseekingalpha.com·95d ago·Neutral
Travere Therapeutics: Valuation Suggests A Buy Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.
View source ↗ - Newsmarketbeat.com·96d ago·Neutral
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $0.44 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$-0.55 vs $-0.06miss
- Tue, Aug 4$-0.37 vs $-0.13miss
- Mon, May 4$-0.39 vs $-0.30miss
- Thu, Feb 19$0.03 vs $0.03beat
- Thu, Oct 30$0.28 vs $-0.31beat
- Wed, Aug 6$-0.14 vs $-0.28beat
Estimates and results for TVTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TVTX officers and directors.
- Bought
- —
- Sold
- $80.1m
0 trades
49 trades
- Dube Eric Msold
- Dube Eric Msold
- Dube Eric Msold
- Heerma Petersold
- Dube Eric Msold
- Dube Eric Msold
- Rote William E.sold
- Rote William E.sold
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TVTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
